Sotera Health (NASDAQ:SHC) Announces Earnings Results

Key Points

• Sotera Health beat Q1 expectations with EPS $0.18 vs. $0.17 and revenue of $280.05M (+~10% YoY), with adjusted EBITDA and margins improving; the company reiterated its FY2026 outlook and set an EPS guidance of $0.93–$1.01.
• Nordion outperformed, delivering ~25.8% constant‑currency revenue growth and >290 bps of margin expansion, while Nelson Labs saw revenue decline (~3.8% CC) and segment income fall about 15% CC.
• Management announced a planned CEO transition to Alton Shader (effective May 26) and disclosed a favorable legal development (Georgia courts dismissed eight bellwether EO cases), but the stock fell ~5% amid concerns over high leverage (debt/equity ~3.66) and a large insider sale (GTCR sold 10M shares).

Sotera Health (NASDAQ:SHC - Get Free Report) announced its earnings results on Tuesday. The company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.17 by $0.01, FiscalAI reports. The firm had revenue of $280.05 million for the quarter, compared to analysts' expectations of $270.78 million. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.Sotera Health's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 EPS. Sotera Health updated its FY 2026 guidance to 0.930-1.010 EPS.

Here are the key takeaways from Sotera Health's conference call:

• Consolidated Q1 results beat expectations with 6.5% constant-currency revenue growth, 6.9% constant-currency Adjusted EBITDA growth, ~20 bps of margin expansion and Adjusted EPS up ~29% year-over-year.
• Nordion outperformed, delivering 25.8% constant-currency revenue growth and >290 bps of margin expansion (56.4% segment margin) driven by harvest timing, mix and pricing.
• Nelson Labs saw revenue decline (3.8% constant-currency) and segment income fall ~15% CC in Q1, though management expects margins to improve to the low‑to‑mid 30s over the year.
• Material legal development — Georgia state courts dismissed all 8 bellwether EO personal-injury cases (subject to appeal), which the company says undermines plaintiffs' general causation theories and supports its defense posture.
• Leadership and balance-sheet items — CEO succession announced (Alton Shader effective May 26; Michael Petras moves to executive chair), management reaffirmed full‑year 2026 guidance, reported ~ $900M liquidity, Q1 net leverage of 3.2x nearing the 2–3x target, and 2026 capex guidance of $175–$225M.

Sotera Health Trading Down 5.2%

Shares of SHC traded down $0.80 during trading hours on Tuesday, hitting $14.59. The stock had a trading volume of 2,900,257 shares, compared to its average volume of 2,520,239. The company has a debt-to-equity ratio of 3.66, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $4.16 billion, a P/E ratio of 54.13 and a beta of 1.82. The company's fifty day simple moving average is $15.04 and its 200 day simple moving average is $16.49. Sotera Health has a 12-month low of $10.80 and a 12-month high of $19.85.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q1 results beat consensus: Sotera reported GAAP and adjusted EPS of $0.18, above the $0.17 consensus, with revenue rising ~10% year-over-year and adjusted EBITDA up ~10%, showing margin improvement. Read More.
• Positive Sentiment: Company reaffirmed FY2026 outlook: Management reiterated full-year guidance for mid-single-digit revenue and Adjusted EBITDA growth on a constant-currency basis and provided FY EPS range of $0.93–$1.01, which overlaps sell‑side expectations. Read More.
• Neutral Sentiment: Guidance detail vs. consensus: The company’s FY EPS band (0.93–1.01) sits around analyst consensus (~0.95), giving investors a mixed read — the range allows upside but also indicates caution. Read More.
• Neutral Sentiment: Planned leadership transition announced: Alton Shader (CEO of Viant Medical) will take over as CEO effective May 26; current CEO Michael Petras will become Executive Chairman — a planned change that reduces surprise risk but may prompt short-term uncertainty. Read More.
• Negative Sentiment: Valuation and balance‑sheet considerations may cap upside: SHC trades at a relatively elevated PE and carries significant leverage (debt/equity ~3.66), which can amplify downside if growth or margins slip. Read More.

Insider Buying and Selling

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $15.27, for a total value of $152,700,000.00. Following the transaction, the director directly owned 12,735,301 shares of the company's stock, valued at $194,468,046.27. This trade represents a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SHC. EverSource Wealth Advisors LLC raised its position in Sotera Health by 831.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company's stock valued at $37,000 after purchasing an additional 2,935 shares during the period. Wells Fargo & Company MN raised its position in Sotera Health by 736.5% in the fourth quarter. Wells Fargo & Company MN now owns 4,283 shares of the company's stock valued at $76,000 after purchasing an additional 3,771 shares during the period. Quadrant Capital Group LLC purchased a new position in Sotera Health in the third quarter valued at about $86,000. Los Angeles Capital Management LLC purchased a new position in Sotera Health in the fourth quarter valued at about $90,000. Finally, PNC Financial Services Group Inc. raised its position in Sotera Health by 10.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company's stock valued at $127,000 after purchasing an additional 705 shares during the period. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SHC. Piper Sandler upgraded Sotera Health from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $17.00 to $24.00 in a report on Friday, January 9th. Royal Bank Of Canada began coverage on Sotera Health in a report on Thursday, January 8th. They set an "outperform" rating and a $24.00 price objective on the stock. Wells Fargo & Company cut Sotera Health to an "overweight" rating in a report on Thursday, January 8th. Citigroup raised their price objective on Sotera Health from $21.00 to $23.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. Finally, Zacks Research cut Sotera Health from a "strong-buy" rating to a "hold" rating in a report on Friday, January 30th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.67.

About Sotera Health

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.